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1. Introduction
Myelodysplastic syndromes (MDS) encompass a heterogeneous 
group of clonal haematopoietic disorders characterised by chronic 
and progressive cytopenias resulting from ineffective haematopoiesis. 
Clinically, patients present with symptomatic anaemia, recurrent 
infections and bleeding. The morphological hallmarks of MDS are 
progressive dysplastic features of haematopoietic cells at all stages 
of development in blood and bone marrow. In many patients, 
depending on a number of prognostic factors, MDS transforms 
over time to acute myeloid leukaemia (AML). The latter is usually 
highly resistant to therapy and responses, if they occur, are usually 
short-lived. Treatment of symptomatic anaemia with frequent blood 
transfusions over protracted periods of time puts patients at risk of 
the effects of iron overload.
In the past decade, our understanding of the pathogenesis of 
MDS has improved greatly. Furthermore, the classification of 
MDS into different clinicopathological sub-groups is undergoing 
constant change and novel treatments are increasing our 
therapeutic options. In addition to the use of allogeneic stem 
cell transplantation, high-dose chemotherapy and growth factor 
support, a number of new drugs were recently approved by the US 
Food and Drug Administration (FDA) and the European Medicine 
Authority (EMEA) in Europe for patients with MDS. These include 
lenalidomide (currently awaiting Medicines Control Council 
(MCC) approval in South Africa and available only through 
named-patient section 21 MCC application) and two inhibitors of 
DNA methyltransferase (hypomethylating agents), azacitidine and 
decitabine. Decitabine has not been registered in South Africa yet, 
but is also available on a named-patient section 21 application basis.
Although these products were originally approved on the basis 
of response rates, transfusion requirements and improvements 
in quality of life, survival data were lacking. This changed with 
evidence of improved overall survival and an increase in the time 
to progression to AML with the demethylating agent azacitidine.1,2 
These benefits were apparent even in subgroups with unfavourable 
karyotypes. The data were recently confirmed in the large, 
prospective, international, multicentre, open-label, randomised 
phase III AZA 001 trial,3 and have led to changes in international 
guidelines, such as the US-based National Comprehensive 
Cancer Network (NCCN), which now include azacitidine in their 
therapeutic algorithms.
2. Limitations of the guidelines
The recommendations represent a consensus view on reasonable 
methods of management applicable to most patients, but do not 
exclude other reasonable management options, and success cannot 
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treatment. Novel agents and their indications are discussed and 
recommendations are made based on best available evidence and 
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Conclusion. Correct diagnosis, risk stratification and 
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the management of patients with MDS.
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be guaranteed in every situation. The unique circumstances of each 
patient should be taken into account by the responsible specialist 
regarding decisions on any specific therapy.
3. Objective
Our objective was to review the National Comprehensive Cancer 
Network (NCCN) 2009, 2010 and 2011 practice guidelines for the 
different subsets of MDS and adapt or modify their application to the 
South African clinical setting in order to provide recommendations 
for MDS management for South Africa.
4. Methods
A panel of South African experts from the tertiary academic and 
private sectors met in Franschhoek, W Cape, in April 2009 to discuss 
contextualisation of the NCCN MDS clinical practice guidelines in 
the South African setting. After an introductory discussion by author 
VJL, the panel specifically reviewed the treatment options for patients 
in the lower-, intermediate- and higher-risk groups, according 
to the International Prognostic Scoring System (IPSS) categories 
LOW, intermediate-1 (INT-1) and HIGH (IPSS category HIGH, 
INT-2).4 The discussion focused, inter alia, on patients needing 
intensive therapy (including allogeneic stem cell transplantation), 
those needing less or lower-intensity therapy (defined as the use 
of low-intensity chemotherapy or biological response modifiers), 
supportive care, and the evaluation and treatment of disease-related 
symptomatic anaemia.
All discussions were recorded for later transcription and collated 
afterwards. A draft set of recommendations was presented by VJL 
at a follow-up meeting of an expanded panel consisting of clinical 
haematologists and oncologists at Kapama River Lodge in Limpopo, in 
July 2010. These draft recommendations took cognisance of literature 
published since the meeting in 2009, including the updated NCCN 
2010 MDS Clinical Practice Guidelines, as well as data presented at 
the annual meetings of the American Society of Hematology (ASH) 
in December 2009 and the European Haematology Association in 
June 2010. Decisions were made on a consensus basis after active 
debate of the issues at hand. Subsequent changes based on the NCCN 
2011 guidelines were included and discussed on an ad hoc basis 
telephonically and by e-mail among the authors.
The panel concluded that in each prognostic grouping, treatment 
options would be provided, which would allow tailoring of treatment 
in both the state and private sectors depending on the availability of 
treatments.
5. Results 
5.1 Risk stratification
The IPSS categories were used in planning therapeutic options 
because they provide risk-based patient evaluation.4 The panel 
takes cognisance of the fact that the IPSS and the World Health 
Organization (WHO) Prognostic Scoring System (WPSS) are being 
revised, but at this stage the IPSS is still the most extensively used 
system in South Africa. It should also be noted that novel prognostic 
scoring systems based on cytogenetics, co-morbidities and flow 
cytometry have been developed, but are not widely used in the South 
African setting yet.5
Patients with clinically significant cytopenias are usually stratified 
into two major risk groups, namely:
• lower-risk patients – IPSS LOW/INT-1 categories; and
• higher-risk patients – IPSS INT-2/HIGH categories.
Table I summarises the prognostic variables and risk groups with 
regard to scoring and median survival in years, taking different age 
groups (≤60 years, >60 years) into account.
5.2 Aim of treatment
In lower-risk patients, therapy is aimed at haematological 
improvement, whereas for patients with higher-risk disease, limiting 
disease progression and improving survival are considered most 
important. Therapeutic options for consideration include supportive 
care, lower-intensity therapy, high-intensity therapy, biological 
response modifiers, immunosuppressive therapies (ISTs), stem cell 
transplantation and/or a clinical trial.
6. Lower-risk patients 
6.1 Supportive care
All patients should receive supportive care as an adjunct to treatment, 
which includes observation, monitoring, transfusion of blood and 
blood products, psychosocial support and attending to quality of 
life issues. Red blood cell (RBC) transfusions (for symptomatic 
Table I. IPSS classification and its prognostic significance4
Points
Prognostic variable 0 0.5 1.0 1.5 2.0
Bone marrow blasts (%)* <5 5 - 10 – 11 - 20 21 - 29
Number of cytopenias† 0 - 1 2 - 3 – – –
Cytogenetic category‡ Good Intermediate Poor
Median survival (yrs)
Risk groups Score ≤60 >60 All patients
Low 0 11.8 4.8 5.7
Intermediate I 0.5 - 1.0 5.2 2.7 3.5
Intermediate II 1.5 - 2.0 1.8 1.1 1.2
High ≥2.5 0.3 0.5 0.4
Adapted from Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
*Bone marrow blasts of 20 - 30% may indicate MDS (according to the French-American-British (FAB) classification) or acute myeloid leukaemia (WHO).
†Cytopenias defined as neutrophils <1.8×109/l, platelets <100×109/l, haemoglobin <10 g/dl.
‡Cytogenetics: Good = normal, -Y alone, del(5q) alone or del (20q) alone; Poor = complex (≥3 abnormalities) or chromosome 7 abnormalities; Intermediate = other abnormalities. Note that 
inv16, t(8;21) and t(15;17) indicate AML and not MDS.
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anaemia), platelet transfusions (for severe thrombocytopenia or 
thrombocytopenic bleeding), antibiotics and antifibrinolytic agents 
are all frequently used as part of supportive care. In addition, 
iron chelation (to manage iron overload) and recombinant human 
erythropoietin (EPO) with or without human granulocyte colony-
stimulating factor (G-CSF) may be useful in selected patients.
6.2 RBC and platelet transfusions
Decision-making on transfusion need is similar to other indications, 
but as patients are often older with co-morbid conditions, the threshold 
for RBC transfusion may be higher (i.e. higher haemoglobin levels) 
and needs to be individualised to patients’ symptoms and tolerance 
of chronic anaemia. As patients require recurrent transfusions, the 
use of pre-storage leukocyte-depleted blood is recommended to 
decrease the risks of platelet isosensitisation, viral infections, febrile 
transfusion reactions and immunosuppression. Platelets are generally 
only given to patients who are actively bleeding, except for those 
receiving active therapy (for example, allogeneic haematopoietic stem 
cell transplantation (HSCT), intensive chemotherapy, hypomethylating 
agents, IST), where prophylactic platelet transfusion may be appropriate. 
The use of universal irradiation of blood products is controversial, with 
the exception of patients considered for allogeneic HSCT.
6.3 Transfusion dependence and iron chelation
Iron overload is a frequent problem in chronically transfused patients. 
It has been shown that both transfusion dependency and elevated 
serum ferritin levels are associated with a decreased overall survival and 
possibly an increased risk for transformation to AML independently of 
cytogenetic risk groups.6-11 The effect on survival was more apparent 
in the lower-risk groups,10 in patients who were actively monitored 
for iron overload, and in patients undergoing HSCT.12,13 Iron chelation 
has been shown to significantly improve survival in heavily transfused 
patients in retrospective studies.14-17 In the prospective EPIC trial, 
deferasirox has been shown to be safe and effective in decreasing 
serum ferritin, alanine transaminase (ALT) and labile plasma iron 
(LPI) in 341 MDS patients with serum ferritin values >2 500 ng/ml.18,19 
A recent consensus statement was published regarding the criteria for 
iron chelation in patients with transfusional iron overload in MDS 
(see Table II).20 The panel felt that these consensus guidelines can be 
applied in the South African setting. In patients whose haemoglobin 
normalises in response to treatment of their MDS, venesection is 
a reasonable alternative to consider for the management of iron 
overload. In most patients this will not be possible, and iron chelation 
with the oral iron chelator deferasirox, or continuous subcutaneous or 
intravenous infusions of deferrioxamine, should be considered. The 
ease of use of deferasirox makes this drug the iron chelator of choice in 
the setting of MDS. The aim should be to decrease serum ferritin levels 
to a target range of between 500 and 1 000 µg/l. Once the target range 
is achieved, the dosage of the iron chelator may be adjusted to maintain 
the patient within this range. A decrease in dose or interruption of the 
iron chelator is usually required once the serum ferritin level decreases 
below 500 µg/l.
It should be noted that, according to South African 
recommendations, deferasirox is contra-indicated in patients with 
high-risk MDS, in patients with a creatinine clearance <60 ml/min, 
and in patients with other haematological and non-haematological 
malignancies who are not expected to benefit from chelation therapy 
owing to rapid disease progression and limited life expectancy. 
Cases of acute renal failure, hepatic failure and fatal gastro-intestinal 
haemorrhage have been reported, with the latter occurring especially 
in elderly patients with advanced haematological malignancies and/
or low platelet counts. Most of the patients who developed these 
problems had co-morbid diseases that put them at risk for these 
complications. Table II summarises the criteria for iron chelation 
therapy in MDS, and which patients with MDS are most likely to 
benefit from iron chelation.
6.4 Management and prevention of infections
Infection, especially in neutropenic patients, is a major cause of 
death in patients with MDS and needs to be treated aggressively and 
appropriately. Broad-spectrum antibiotics are usually required for 
patients with neutropenic fever. The use of prophylactic antibiotics 
is less clear and they are not routinely recommended for all patients, 
but individual patients receiving treatments that put them at high risk 
for neutropenic fever may benefit from antibacterial and antifungal 
prophylaxis. This decision needs to be individualised taking into 
account the patient’s clinical condition, intensity of treatment, 
neutropenic fever risk and co-morbid conditions. It should also be 
noted that iron overload has been associated with a higher risk of 
bacterial and fungal infections.21
7. Patients with symptomatic anaemia
Beyond the adjunctive measures of supportive care, patients 
are stratified according to whether they primarily present with 
symptomatic anaemia, thrombocytopenia or neutropenia. 
Symptomatic, transfusion-dependent anaemia is a common and 
important manifestation of MDS. It has been associated with reduced 
quality of life, iron overload and other complications of transfusions 
and the need for iron chelation therapy. Also, the cost of transfusion 
and iron chelation may be considerable.
7.1 Deletion 5q- ± other cytogenetic abnormalities
The NCCN guidelines recommend the use of lenalidomide in patients 
with del 5q. Lenalidomide has been shown to yield transfusion 
independence in 67% of lower-risk patients with del 5q and a median 
duration of response of more than 2 years.7 Cytogenetic responses 
were seen in 73% of patients (45% major and 28% minor), with 
Table II. Iron chelation in myelodysplastic syndromes20
Criteria for iron chelation therapy in MDS
•  When serum ferritin levels reach 1 000 μg/l, depending on 
transfusion rate
•  Patient’s transfusion need is ≥2 units RCC/month and persists 
at this level for >1 year
•  Patient is ineligible to receive or unresponsive to primary 
therapy, e.g. hormonal or hypomethylation therapy
Patients with MDS most likely to benefit from iron chelation
•  Transfusion-dependent patients requiring 2 units RCC/
month for >1 yr
• Patients with s-ferritin >1 000 μg/l
• Patients with low-risk MDS
• IPSS: Low or Int-I
• WHO: RA, RARS, or 5q−
• Patients with a life expectancy ≥1 yr
• Patients without co-morbidities that would limit prognosis 
• Candidates for HSCT
• Patients in whom there is a need to preserve organ function
Adapted from Bennett JM. Consensus statement on iron overload in myelodysplastic 
syndromes. Am J Hematol 2008;83:858-861.
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grade 3 or 4 myelosuppression during the first 3 months as the 
most prominent adverse events.7,22,23 Although lenalidomide has 
been approved by the FDA, the EMEA has been concerned about a 
potential increased risk of progression to AML in patients with del 
5q. Preliminary results from a number of prospective clinical trials 
seem to be reassuring.23-25
7.2 Erythropoiesis-stimulating agents ± G-CSF
A number of phase II clinical trials have shown response rates 
of 20 - 40% with single-agent erythropoiesis-stimulating agents 
(ESAs), with even higher response rates when treatment is instituted 
early.26 Combining ESAs with granulocyte-colony stimulating factor 
(G-CSF) may enhance response, owing to a synergistic effect.27-29 In a 
large cohort of 403 patients with MDS who received epoietin-alpha, 
epoietin-beta or darbepoietin with or without G-CSF, responses were 
seen in 62% of patients according to the International Working Group 
200030 (IWG) criteria (40% major and 22% minor). Response duration 
(measured from onset rEPO) was 20 months (range 3 - 74 months).30 
A meta-analysis of anaemic MDS patients confirmed the usefulness of 
epoietin-alpha and darbepoietin in the treatment of MDS.31
To manage these patients as cost-effectively as possible, the subsets 
of patients most likely to benefit need to be recognised.32 The strongest 
association with response to treatment has been seen in patients with 
EPO levels ≤500 mµ/ml and RBC transfusion needs.32 The serum 
EPO level cut-off point of 500 mU/ml (or U/l) was derived from two 
large phase II studies followed by validation in a prospective clinical 
Fig. 1. Algorithm for the management of the IPSS Categories LOW and INT-1.
Adapted and modified with permission from the NCCN Clinical Practice 
Guidelines in Oncology (NCCN Guidelines™) for Myelodysplastic Syndromes 
V.2.2011 (National Comprehensive Cancer Network, Inc., 2011, all rights re-
served). The NCCN Guidelines™ and illustrations therein may not be repro-
duced in any form for any purpose without the express written permission 
of the NCCN. To view the most recent and complete version of the NCCN 
Guidelines, go online to NCCN.org. NATIONAL COMPREHENSIVE CAN-
CER NETWORK®, NCCN®, NCCN GUIDELINES™, and all other NCCN con-
tent are trademarks owned by the National Comprehensive Cancer Network, 
Inc. *Indicates a deviation from the NCCN Guidelines based on local expert 
opinion and availability of therapeutic agents in South Africa.
Fig. 2. Algorithm for the management of the IPSS Categories INT-2 and HIGH.
Adapted and modified with permission from the NCCN Clinical Practice Guide-
lines in Oncology (NCCN Guidelines™) for Myelodysplastic Syndromes V.2.2011 
(National Comprehensive Cancer Network, Inc., 2011, all rights reserved). The 
NCCN Guidelines™ and illustrations therein may not be reproduced in any 
form for any purpose without the express written permission of the NCCN. 
To view the most recent and complete version of the NCCN Guidelines, go on-
line to NCCN.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, 
NCCN®, NCCN GUIDELINES™, and all other NCCN content are trademarks 
owned by the National Comprehensive Cancer Network, Inc. *Indicates a devia-
tion from the NCCN Guidelines based on local expert opinion and availability 
of therapeutic agents in South Africa.
GUIDELINE
903December 2011, Vol. 101, No. 12  SAMJ
trial.29 The likelihood of response to EPO and G-CSF in a patient with 
a serum EPO level ≤500 mU/ml and a transfusion need of less than 2 
units of RBCs per month was 74%. In contrast, patients with an EPO 
level >500 mU/ml and a transfusion need of ≥2 units per month only 
have a 7% chance of response.29 It is critical to identify these patients 
who are unlikely to respond, as they also have an increased possibility 
of disease progression, especially if other more appropriate therapies, 
such as allogeneic HSCT and azacitidine, are delayed.33
The effect of treatment on long-term outcomes has been 
favourable, but survival benefit was only seen in patients with a 
moderate pretreatment transfusion need of less than 2 units of RBCs 
per month.30,34,35 A recent study has further shown clear improvement 
in quality of life in responding patients that correlated with decreases 
in transfusion requirements.36 Most responses are seen within 12 
weeks of treatment onset, with a median duration of response of 
about 2 years.30,34,37 The risk of progression to higher-risk MDS and 
AML does not seem to increase compared with patients treated with 
transfusion alone.30,34
The panel concluded that the stratification of low-risk patients 
into symptomatic anaemia, thrombocytopenia or neutropenia and 
according to serum EPO levels was valid, as was stratifying patients 
according to serum EPO levels. The use of ESAs in combination with 
G-CSF was supported in selected patients, taking into account the 
likelihood of response in an individual patient. In patients with a low 
likelihood of response, alternative therapies should be considered.
7.3 Failure to respond to ESA
In patients not responding to ESA and G-CSF, the available options 
in South Africa include hypomethylating agents, IST, a clinical trial 
or allogeneic HSCT in selected patients.
7.4 Anaemic patients with serum EPO level >500 mU/ml
These patients should be evaluated to determine whether they have 
a good probability of responding to IST, or whether they would be 
candidates for the use of a hypomethylating agent.
7.5 Immunosuppressive therapy
Patients most likely to respond to IST include IPSS LOW or 
INT-1 patients with one or more of the following features: <60 
years old, HLA-DR15+, the presence of a paroxysmal nocturnal 
haemoglobinuria (PNH)-positive clone, or hypocellular bone 
marrow. Also, patients with a recent onset of RBC transfusion 
requirement, very few or no blasts and normal cytogenetics 
seem to respond better to IST.38-42 In these selected patients, 
antithymocyte globulin (ATG) in combination with cyclosporin 
should be considered, as responses can be expected in 30 - 40% of 
lower-risk patients resistant to EPOs. The panel concurred with the 
treatment pathway defined by the NCCN, i.e. that if patients are 
non-responders to IST, they would be considered for treatment with 
hypomethylating agents or a clinical trial.
Patients with a low probability of responding to IST should be 
considered for treatment with hypomethylating agents or a clinical 
trial. Once available, lenalidomide may become an appropriate option 
in selected patients. Patients not responding to any of these could be 
considered for allogeneic HSCT.
It is worth noting that very promising results have been seen in 
small studies with novel immunosuppressive regimens. In one study,43 
alemtuzumab 10 mg/day was given for 10 days, with responses seen 
in 17 (77%) out of 22 patients with evaluable INT-1 disease, and in 4 
(57%) out of 7 with evaluable INT-2 disease. Median time to response 
in this study was 3 months.43
7.6 Patients with predominant thrombocytopenia and/
or neutropenia
In clinical practice, patients with true isolated neutropenia have 
shown very good responses to the addition of growth factors. As 
such, patients should be given a trial of growth factors or azacitidine, 
or be considered for a clinical trial. In the event of no or limited 
response, IST or allogeneic HSCT should be considered. The role and 
safety of romiplostim in MDS has not been fully delineated.
8. Higher-risk patients (IPSS INT-2/
HIGH)
Therapeutic options for higher-risk patients include allogeneic 
HSCT, high-intensity therapy, low-dose chemotherapy (for example, 
low-dose cytarabine), hypomethylating agents, and an array of novel 
experimental agents or supportive care.
Patients in the INT-2 and HIGH risk categories according to the 
IPSS have a median survival of only 1.2 and 0.4 years, respectively. 
Time to AML progression is generally less than 1 year.4 Taking into 
account the very poor outcomes in this patient group, patients should 
be carefully evaluated and offered treatment that will positively change 
outcome and survival. Treatment for higher-risk patients is therefore 
dependent on whether they are felt to be candidates for intensive 
therapy, such as allogeneic HSCT or intensive chemotherapy.
Factors that influence this decision include patient age, performance 
status, absence of major co-morbid conditions, psychosocial status, 
and the availability of an HLA-matched donor. MDS is generally 
a disease of older patients who should be carefully evaluated 
for co-morbid disease that may influence their ability to tolerate 
intensive chemotherapy and/or HSCT. The HSCT co-morbidity 
index has been shown to be an accurate predictor of non-relapse 
mortality after HSCT.44-46 The panel agreed that the timing and 
selection of MDS patients for HSCT was critical. IPSS INT-2 and 
HIGH risk patients ≤60 years old should ideally proceed to allogeneic 
HSCT as early as possible. In LOW or INT-1 risk patients, HSCT is 
usually delayed until evidence of disease progression is observed. 
Non-myeloablative HSCT is usually preferred in order to reduce 
treatment-related mortality, except in younger patients, where full 
myeloablation is still often used.47 It has been suggested that potential 
transplant candidates may benefit from azacitidine pre-transplant 
during the period in which the donor search is ongoing, especially in 
patients with an unfavourable karyotype. Patients with unfavourable 
karyotypes are usually refractory to conventional chemotherapy. This 
concurs with the NCCN guidelines, that qualify the option of HSCT 
with the fact that azacitidine may be used as a bridge to transplant 
while awaiting improved patient status or donor availability. In 
patients with a more favourable karyotype, intensive chemotherapy 
may be useful to decrease blast percentages pre-transplant and thus 
limit post-transplant relapse rates.
8.1 High-intensity therapy
Intensive therapy is usually limited to patients less than 65 years of 
age with more favourable karyotypes and no allogeneic stem cell 
donor. In patients with unfavourable karyotypes, hypomethylating 
agents are preferred. In older patients, azacitidine is the treatment of 
choice,48 although careful attention to co-morbid disease is required. 
Anthracyclines and cytarabine combinations remain the preferred 
choice for intensive chemotherapy, and complete remission (CR) rates 
of between 40% and 60% are usually attained. Unfortunately, CR is not 
often sustained, with a median duration of CR of less than 12 months, 
with less than 10% of patients achieving a prolonged CR. Toxicity is 
often higher than that seen in patients treated for AML with similar 
regimens, and is often characterised by prolonged cytopenias due 
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to bone marrow hypoplasia.49-51 Patients who generally benefit most 
from intensive chemotherapy are younger patients with favourable 
cytogenetics. Complete remission rates are low and CR duration is 
generally short in patients with an unfavourable karyotype.
In higher-risk patients, a clinical trial with an azacitidine-based 
combination may be considered before intensive treatment, especially 
in older patients. This is supported by data from the AZA 001 trial,3 
a large, international, multicentre, open-label, randomised phase III 
trial. Findings demonstrated improved overall survival rates at 2 years 
(50.8% v. 26.2%) using azacitidine when compared with conventional 
care (best supportive care, intensive chemotherapy and low-dose 
cytarabine).3 This benefit in overall survival was independent of age, 
karyotype, the number of bone marrow blasts and the FAB or WHO 
type.3 Of note was the survival advantage seen in patients with poor-
risk cytogenetics (-7/7q-) in all patient groups receiving azacitidine.48 
It is important to emphasise that responses often occurred only after 
4 - 6 cycles, with the median number of cycles being 9 and 14 given to 
non-responders and responders, respectively.3 In another analysis of 
the AZA 001 trial, azacitidine was shown to improve overall survival 
when compared with low-dose cytarabine, with fewer grade 3 - 4 
cytopenias in the azacitidine group.48 A useful prognostic scoring 
system has been developed to predict responses to azacitidine.52
A second demethylating agent, decitabine, has not been found to 
confer a survival advantage in controlled trials, but this may at least 
in part have been due to the nature of the trials, in which therapy 
was limited to 4 cycles and a mixed population of MDS patients 
were treated.53,54 A more recent prospective, randomised phase III 
study55 showed that decitabine may lead to responses in older MDS 
patients, but without a significant improvement in overall and AML-
free survival. Transformation to AML was significantly decreased in 
this study. In this study, multivariate analysis showed that patients 
with a shorter duration of MDS had a worse outcome when given 
decitabine.55
Treatment options for patients who are not candidates for intensive 
therapy are similar to those in low-risk patients, being azacitidine-
based regimens, supportive care, low-dose cytarabine or other 
experimental agents where available and appropriate. Older patients 
with poor-risk cytogenetics, who are not eligible for intensive 
chemotherapy, are usually offered an azacitidine-based therapy or 
best supportive care.
8.2 Non-intensive therapy
As a relatively low-cost intervention, low-dose cytarabine, given at a 
dose of 20 mg/m2/d for 14 - 21 days out of every month, may yield 
partial and complete remission rates of 20% and 15%, respectively. 
These responses are generally limited to patients without poor-
risk cytogenetics and are usually short-lived.48 Myelosuppression 
is very common, with grade 3 - 4 anaemia, neutropenia and 
thrombocytopenia seen in up to 77%, 89% and 96% of patients, 
respectively. Compared with azacitidine, response rates were fewer 
and shorter, overall survival lower and toxicity higher.48 Low-dose 
cytarabine could be considered as an adjunct to supportive care if 
azacitidine treatment has failed or is not available.
9. Experimental agents
It is generally felt that patients should be included in clinical trials as 
far as possible. Many new agents and drug combinations are being 
investigated. In patients with higher-risk MDS who are eligible for 
a transplant and have an available donor, allogeneic HSCT with or 
without a preceding hypomethylating agent is the treatment of choice. 
In all other patients, a hypomethylating agent would be the treatment 
of choice. In case of failure or loss of response after a hypomethylating 
agent, intensive chemotherapy or low-dose cytarabine are therapeutic 
options that may be considered. Supportive care should be offered to 
all patients while taking individual risk-benefit factors into account 
when making decisions on the use of more expensive treatment 
modalities, such as growth factors, EPOs and iron chelation.
10. Conclusion
The management of MDS is a complex process requiring expertise 
and skills in managing the complications of the disease as well 
as complications of treatment used. Continuous progress in the 
understanding of the molecular pathogenesis of MDS has led to 
the development of a number of therapeutic agents with acceptable 
side-effect profiles and improvements in survival and quality of life 
of MDS patients. The results from ongoing, prospective, randomised 
trials on novel agents and therapeutic combinations are eagerly 
awaited.
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